Adverse events of local treatment in long-term head and neck rhabdomyosarcoma survivors after external beam radiotherapy or AMORE treatment. Issue 11 (July 2015)

• Record Type: Journal Article
• Authors: Schoot, Reineke A.; Slater, Olga; Ronckers, Cécile M.; Zwinderman, Aeilko H.; Balm, Alfons J.M.; Hartley, Benjamin; van den Brekel, Michiel W.; Gupta, Sanjeev; Saeed, Peerooz; Gajdosova, Eva; Pieters, Bradley R.; Gaze, Mark N.; Mandeville, Henry C.; Fajardo, Raquel Davila; Chang, Yen Ch'ing; Gains, Jennifer E.; Strackee, Simon D.; Dunaway, David; Abela, Christopher; Mason, Carol; Smeele, Ludi E.; Chisholm, Julia C.; Levitt, Gill A.; Kremer, Leontien C.M.; Grootenhuis, Martha A.; Maurice-Stam, Heleen; Stiller, Charles A.; Hammond, Peter; Caron, Huib N.; Merks, Johannes H.M.
• Is Part Of: European journal of cancer. Volume 51:Issue 11(2015:Jul.)
• Page Start: 1424
• Page End: 1434
• Publication Date: 2015-07
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.02.010
• Languages: English
• ISSNs: 0959-8049

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab015"> <title id="st235">Abstract</title> <sec> <title id="st190">Background</title> <p id="sp0015">Radiotherapy is a well-known cause of adverse events (AEs). To reduce AEs, an innovative local treatment was developed in Amsterdam: <underline>A</underline>blative surgery, <underline>MO</underline>uld brachytherapy and surgical <underline>RE</underline>construction (AMORE).</p> <p id="sp0025"> <italic>Aims:</italic> (1) to determine the prevalence of AEs in HNRMS survivors and (2) to compare AEs between survivors treated with the international standard: external beam radiotherapy (EBRT-based: London) and survivors treated with AMORE if feasible, otherwise EBRT (AMORE-based: Amsterdam).</p> </sec> <sec> <title id="st195">Methods</title> <p id="sp0030">All HNRMS survivors, treated in London or Amsterdam between January 1990 and December 2010 (<italic>n</italic> = 153), and alive ⩾2 years post-treatment were eligible (<italic>n</italic> = 113). A predefined list of AEs was assessed in a multidisciplinary clinic and graded according to the Common Terminology Criteria for Adverse Events.</p> </sec> <sec> <title id="st200">Results</title> <p id="sp0035">Eighty HNRMS survivors attended the clinic (median follow-up 10.5 years); 63% experienced ⩾1 severe or disabling event, and 76% had ⩾5 AEs (any grade). Survivors with EBRT-based treatment were, after adjustment for site, age at diagnosis, and follow-up duration, at increased risk to develop any grade 3/4 event or ⩾5 AEs (any grade) compared with survivors with AMORE-based treatments (<italic>p </italic>= 0.032 and 0.01, respectively). Five year overall survival (source population) after EBRT-based treatment was 75.0%, after AMORE-based treatment 76.9%, <italic>p</italic> = 0.56.</p> </sec> <sec> <title id="st205">Conclusion</title> <p id="sp0040">This study may serve as a baseline inventory and can be used in future studies for prospective assessments of AEs following the introduction of novel local treatment modalities. AMORE-based local treatment resulted in similar overall survival and a reduction of AEs secondary to local treatment.</p> </sec> </abstract>